---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-003256"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:05:55.117085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports 96% procedural success at 12 months for nPulse AF ablation study

## Summary
- 100% procedural success at 6 months (75/75); 96% at 12 months (45/47) in first-in-human feasibility study.
- Average procedure time 65 ± 28 min; left atrial dwell time 21 ± 13.3 min; fluoroscopy 9.8 ± 5.8 min.
- Safety: 1.3% (2/150) subjects had a serious adverse event related to primary safety endpoint.
- Data presented at AF Symposium 2026 by Dr. Vivek Reddy; 165 patients treated across 9 European sites.
- Company plans to initiate pivotal IDE study in Europe and U.S. following these results.

## SEC filing metadata
- accession: 0001437749-26-003256
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926003256/0001437749-26-003256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926003256/plse20260204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-003256
- JSON: https://secwatch.observer/filing/0001437749-26-003256.json
- Plain text: https://secwatch.observer/filing/0001437749-26-003256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.